Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.
Hellmann MD, Chaft JE, William WN Jr, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG; University of Texas MD Anderson Lung Cancer Collaborative Group. Hellmann MD, et al. Among authors: pisters km. Lancet Oncol. 2014 Jan;15(1):e42-50. doi: 10.1016/S1470-2045(13)70334-6. Lancet Oncol. 2014. PMID: 24384493 Free PMC article. Review.
Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer.
Zinner RG, Komaki R, Cox JD, Glisson BS, Pisters KM, Herbst RS, Kies M, Liao Z, Hong WK, Fossella FV. Zinner RG, et al. Among authors: pisters km. Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):119-27. doi: 10.1016/j.ijrobp.2008.03.069. Epub 2008 Jun 14. Int J Radiat Oncol Biol Phys. 2009. PMID: 18556142 Clinical Trial.
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G Jr, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. Herbst RS, et al. Among authors: pisters km. Cancer. 2002 Jul 15;95(2):340-53. doi: 10.1002/cncr.10629. Cancer. 2002. PMID: 12124835 Free article. Clinical Trial.
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB Jr, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Swisher SG, et al. Among authors: pisters km. Clin Cancer Res. 2003 Jan;9(1):93-101. Clin Cancer Res. 2003. PMID: 12538456 Clinical Trial.
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.
Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Fritsche HA Jr, Ro JY, Ordonez NG, Tran HT, Yang Y, Smith TL, Mass RD, Herbst RS. Zinner RG, et al. Among authors: pisters km. Lung Cancer. 2004 Apr;44(1):99-110. doi: 10.1016/j.lungcan.2003.09.026. Lung Cancer. 2004. PMID: 15013588 Clinical Trial.
Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR. Kim ES, et al. Among authors: pisters km. Cancer. 2005 Aug 1;104(3):561-9. doi: 10.1002/cncr.21188. Cancer. 2005. PMID: 16028213 Free article. Clinical Trial.
Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer.
Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR Jr, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Zinner RG, et al. Among authors: pisters km. Cancer. 2005 Dec 1;104(11):2449-56. doi: 10.1002/cncr.21480. Cancer. 2005. PMID: 16258975 Free article. Clinical Trial.
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline.
Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, Somerfield MR, Brouwers MC, Darling G, Ellis PM, Gaspar LE, Pass HI, Spigel DR, Strawn JR, Ung YC, Shepherd FA; Cancer Care Ontario; American Society of Clinical Oncology. Pisters KM, et al. J Clin Oncol. 2007 Dec 1;25(34):5506-18. doi: 10.1200/JCO.2007.14.1226. Epub 2007 Oct 22. J Clin Oncol. 2007. PMID: 17954710
Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220.
Kernstine KH, Moon J, Kraut MJ, Pisters KM, Sonett JR, Rusch VW, Thomas CR Jr, Waddell TK, Jett JR, Lyss AP, Keller SM, Gandara DR; American College of Surgeons Oncology Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; National Cancer Institute of Canada Clinical Trials Group; Southwest Oncology Group. Kernstine KH, et al. Among authors: pisters km. Ann Thorac Surg. 2014 Aug;98(2):402-10. doi: 10.1016/j.athoracsur.2014.04.129. Epub 2014 Jun 28. Ann Thorac Surg. 2014. PMID: 24980603 Free PMC article. Clinical Trial.
89 results